Sealey J E, von Lutterotti N, Rubattu S, Campbell W G, Gahnem F, Halimi J M, Laragh J H
Cardiovascular Center, Cornell University Medical College, New York, New York 10021.
Am J Hypertens. 1991 Dec;4(12 Pt 1):972-7. doi: 10.1093/ajh/4.12.972.
A greater renin system is proposed. Evidence is presented that a greater renin system exists that has both vasodilator and vasoconstrictor properties. Vasodilator activity is induced by prorenin, vasoconstrictor activity by renin. Our model is based on evidence that both prorenin and renin have the capacity to generate angiotensin and that angiotensin causes vasodilation at high concentrations and vasoconstriction at low concentrations. In our model, prorenin acts only at particular target sites while renin of renal origin acts via the general circulation. Prorenin's designation as a biosynthetic precursor implies lack of intrinsic catalytic activity whereas in fact it can become reversibly active. Activation may occur in vivo at binding sites without cleavage of the prosequence. In this framework, prorenin should be more aptly called renin I and circulating active renin, renin II. In our model, the role of renin I (prorenin) is to generate localized high concentrations of angiotensin II, eg, in the afferent arteriole of the kidney and in other vital organs, causing regional dilation by rendering tissues insensitive (tachyphylactic) to the vasoconstrictor effect of circulating angiotensin II or by releasing vasodilator substances. The role of renin II (active renin) is to constrict resistance vessels and the efferent arteriole of the kidney, thereby raising blood pressure, maintaining glomerular filtration rate, and enabling more blood flow to those organs that selectively bind prorenin. This twin control system is ideally designed to maintain blood flow to vital organs.(ABSTRACT TRUNCATED AT 250 WORDS)
提出了一种更完善的肾素系统。有证据表明存在一种具有血管舒张和血管收缩特性的更完善的肾素系统。血管舒张活性由肾素原诱导,血管收缩活性由肾素诱导。我们的模型基于以下证据:肾素原和肾素都有能力生成血管紧张素,且血管紧张素在高浓度时引起血管舒张,在低浓度时引起血管收缩。在我们的模型中,肾素原仅作用于特定的靶位点,而肾源性肾素则通过体循环起作用。将肾素原指定为生物合成前体意味着缺乏内在催化活性,而实际上它可以可逆地激活。激活可能在体内的结合位点发生,而无需切割前序列。在此框架下,肾素原应更恰当地称为肾素I,而循环中的活性肾素称为肾素II。在我们的模型中,肾素I(肾素原)的作用是在局部产生高浓度的血管紧张素II,例如在肾入球小动脉和其他重要器官中,通过使组织对循环中的血管紧张素II的血管收缩作用不敏感(速发耐受)或通过释放血管舒张物质来引起局部扩张。肾素II(活性肾素)的作用是收缩阻力血管和肾出球小动脉,从而升高血压、维持肾小球滤过率,并使更多血液流向那些选择性结合肾素原的器官。这种双重控制系统的设计非常理想,可维持对重要器官的血流供应。(摘要截选至250词)